These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11789360)

  • 1. [Role of phosphate in recurrent calcium lithiasis. A current view].
    Reina Ruiz MC; Conde Sánchez JM; Domínguez Domínguez M; Espinosa Olmedo J; García Pérez M
    Arch Esp Urol; 2001 Nov; 54(9):1029-35. PubMed ID: 11789360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Calcium nephrolithiasis and phosphate therapy. Long term study (65 cases) (author's transl)].
    Lagrue G; Hioco D; Kazandjian M; Cattaneo A; Cassagnol M
    Sem Hop; 1980 Jun 8-15; 56(21-24):1043-8. PubMed ID: 6248982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
    Arrabal-Polo MA; Arias-Santiago S; de Haro-Muñoz T; Lopez-Ruiz A; Orgaz-Molina J; Gonzalez-Torres S; Zuluaga-Gomez A; Arrabal-Martin M
    Urology; 2013 Apr; 81(4):731-7. PubMed ID: 23375914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of fasting hypercalciuria associated with increased citraturia in the ambulatory evaluation of nephrolithiasis.
    Damasio B; Massarino F; Durand F; Banchero R; Bottino P; De Franchis V; Carmignani G; Cannella G
    J Nephrol; 2005; 18(3):262-6. PubMed ID: 16013013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of thiazide therapy in the prophylaxis of calcium lithiasis].
    Fernández Rodríguez A; Arrabal Martín M; García Ruiz MJ; De Haro Muñoz T; Zuluaga Gómez A
    Arch Esp Urol; 2001 Nov; 54(9):1047-54. PubMed ID: 11789362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical determinants of severe lithogenic activity in patients with idiopathic calcium nephrolithiasis.
    Arrabal-Polo MA; Arrabal-Martin M; de Haro-Muñoz T; Poyatos-Andujar A; Palæo-Yago F; Zuluaga-Gomez A
    Urology; 2012 Jan; 79(1):48-54. PubMed ID: 21908029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal phosphate control as a reliable predictive factor of stone recurrence.
    Kim YJ; Kim TH; Yun SJ; Kim ME; Kim WJ; Lee SC
    J Urol; 2009 Jun; 181(6):2566-72; discussion 2572. PubMed ID: 19375105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of idiopathic hypercalciuria and nephrolithiasis with sodium cellulose phosphates.
    Teotia M; Teotia SP; Singh RK; Teotia NP
    J Assoc Physicians India; 1974 Oct; 22(10):709-14. PubMed ID: 4448804
    [No Abstract]   [Full Text] [Related]  

  • 10. [On the question of endocrine side effects in patients on medication for renal calcium stone disease (author's transl)].
    Ziegler R; Uhl K; Minne H; Russmann D; Döring B
    Urologe A; 1980 Jul; 19(4):226-30. PubMed ID: 7414768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of calcium kidney lithiasis. ESWL, NLP, open surgery].
    Boronat Tormo F; Pontones Moreno JL; Broseta Rico E; Oliver Amoros F; Budia Alba A; Jimenez Cruz JF
    Arch Esp Urol; 2001 Nov; 54(9):909-25. PubMed ID: 11789370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of acute acid loading on acid-base and calcium metabolism.
    Osther PJ
    Scand J Urol Nephrol; 2006; 40(1):35-44. PubMed ID: 16452054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of metabolic evaluation and medical treatment for calcium nephrolithiasis in a private urological practice.
    Mardis HK; Parks JH; Muller G; Ganzel K; Coe FL
    J Urol; 2004 Jan; 171(1):85-8. PubMed ID: 14665850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism.
    Parks JH; Coe FL; Evan AP; Worcester EM
    BJU Int; 2009 Mar; 103(5):670-8. PubMed ID: 18793297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic evaluation at the time of the first renal lithiasis episode].
    del Valle EE; Spivacow FR; Zanchetta JR
    Medicina (B Aires); 1995; 55(1):69-74. PubMed ID: 7565040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation.
    Robinson MR; Leitao VA; Haleblian GE; Scales CD; Chandrashekar A; Pierre SA; Preminger GM
    J Urol; 2009 Mar; 181(3):1145-50. PubMed ID: 19152932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stone-forming patients.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Castaldo R; Manno G; Guadagno V; Strazzullo P; Nunziata V
    Urology; 2004 Oct; 64(4):833-8. PubMed ID: 15491743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of calcium-salt renal calculi associated with idiopathic hypercalciuria].
    Oliver J; Liberman UA; de Vries A
    Harefuah; 1971 Dec; 81(11):554-5. PubMed ID: 5142929
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.
    Ekeruo WO; Tan YH; Young MD; Dahm P; Maloney ME; Mathias BJ; Albala DM; Preminger GM
    J Urol; 2004 Jul; 172(1):159-63. PubMed ID: 15201761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence of renal lithiasis.
    Grases F; Costa-Bauzá A; Ramis M; Montesinos V; Conte A
    Scand J Urol Nephrol; 2003; 37(6):482-6. PubMed ID: 14675921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.